Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9cc8457536ed3f4bad52ad3159f05bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1c3b265fcfd6deacdc00a5ef4efb265 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_519ec93058ea845cd8c8533094c64694 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42bafb880871970d57dea45639fd1019 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2010-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_814d4fe8ff9bb52748fabd069d56914d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ada43f305e3e65bebb31cfe71967ff20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_711f33424d8110275f73b00e4b45ed20 |
publicationDate |
2013-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2013072539-A1 |
titleOfInvention |
Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand |
abstract |
A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxy-tamoxifen and also melatonin, with the tamoxifen or 5-hydroxy-tamoxifen and melatonin's being linked by an unsubstituted C 2 -C 4 alkyl liner between the tamoxifen amine and the carbonyl of melatonin. |
priorityDate |
2009-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |